Compendia Bioscience (Michigan) and Althea Diagnostics Develop Breast Cancer Segregation Panel Assay as a Platform for Companion Diagnostic Development (12/8/2010)

Compendia Bioscience provides software to access their collection of cancer genomic information. Compendia Bioscience was co-founded by Daniel R. Rhodes, Ph.D., who is the company’s CEO as well as a part-time faculty researcher at the University of Michigan Center for Translational Pathology, and Arul Chinnaiyan, M.D., PhD., who is a Professor in the Department of Pathology and Urology at the University of Michigan Medical School.

From the company’s press release:
Compendia Bioscience today announced a new strategic partnership with Althea Diagnostics and the immediate availability of the partnership’s first joint product and service offerings — the Breast Cancer Segregation Panel™ Assay and Analysis Service. read full press release

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: